

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT3151519

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST	
CONVEYING PARTY DATA		
Name		Execution Date
PDL BIOPHARMA, INC.		12/16/2014
RECEIVING PARTY DATA		
Name:	VICURON PHARMACEUTICALS INC.	
Street Address:	200 SOUTH WACKER	
Internal Address:	SUITE 2550	
City:	CHICAGO	
State/Country:	ILLINOIS	
Postal Code:	60606	
PROPERTY NUMBERS Total: 17		
Property Type	Number	
Application Number:	10582141	
Patent Number:	7763751	
Application Number:	09248158	
Patent Number:	6977141	
Application Number:	10992564	
Patent Number:	7256177	
Application Number:	10496009	
Patent Number:	7407654	
Application Number:	12147215	
Patent Number:	8007789	
Application Number:	13566646	
Application Number:	10834395	
Patent Number:	8143212	
Application Number:	10714261	
Patent Number:	6900175	
Application Number:	10828439	
Patent Number:	7115564	
CORRESPONDENCE DATA		
Fax Number:	(212)230-8888	
		PATENT

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: megan.stembridge@wilmerhale.com
Correspondent Name: CHRISTOPHER BARNSTABLE-BROWN
Address Line 1: 250 GREENWICH ST, 7 WTC
Address Line 2: WILMERHALE
Address Line 4: NEW YORK, NEW YORK 10007

ATTORNEY DOCKET NUMBER:	2205364-00129
NAME OF SUBMITTER:	MEGAN L. STEMBRIDGE
SIGNATURE:	/Megan L. Stembridge/
DATE SIGNED:	12/17/2014

Total Attachments: 2

source=2014-12-16 release patent#page1.tif
source=2014-12-16 release patent#page2.tif

RELEASE OF PATENT SECURITY AGREEMENT

WHEREAS, Vicuron Pharmaceuticals Inc., a Delaware corporation (the "Grantor"), entered into that certain Patent Security Agreement (the "Agreement"), dated as of October 31, 2013, which was recorded in the United States Patent and Trademark Office on October 31, 2013 at Reel 031529 and Frame 0353, that by its terms granted to PDL BioPharma, Inc., a Delaware corporation (the "Lender"), a security interest and continuing lien in the Patent Collateral (as defined in the Agreement) in favor of the Lender; and

WHEREAS, the Lender has agreed to terminate and release the entirety of its security interest in the Patent Collateral;

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, effective as of even date herewith, the Lender hereby irrevocably (a) releases, relinquishes, terminates and discharges its security interest in the Patent Collateral, including the registrations and applications listed on Exhibit A hereto, and (b) reassigns any and all such right, title and interest (if any) that the Lender may have in the Patent Collateral to the Grantor, and any right, title or interest of the Lender in such Patent Collateral shall hereby immediately cease and become void. The Lender further agrees, for itself, its successors and assigns, to execute such further documents and to perform such further lawful acts as may reasonably be requested by the Grantor, to effectuate this release.

The Lender acknowledges that it is the purpose of this document to memorialize the aforementioned release of its security interest in the Patent Collateral in a form suitable for recordation in the United States Patent and Trademark Office and hereby consents to the recording of this document in the United States Patent and Trademark Office.

IN WITNESS WHEREOF the Lender by the signature below of its duly authorized representative agrees to be bound by the provisions of this release agreement as of the date of execution, this 10 day of December, 2014.

PDL BIOPHARMA, INC.



Name: Christopher Stone
Title: Vice General Counsel

Exhibit A

PATENT SECURITY INTEREST RELEASE

U.S. Patent Registrations/Applications			
Title	Application/Patent Number	Filing Date	Issue Date
HYDROXYLAMINE DERIVATIVES	Appl. No. 10/582,141 Patent No. 7,763,751	07-05-2006	07-27-2010
DIRECT ADSORPTION SCINTILLATION ASSAY FOR MEASURING ENZYME ACTIVITY AND ASSAYING BIOCHEMICAL PROCESSES	Appl. No. 09/248,158 Patent No. 6,977,141	02-09-1999	12-20-2005
LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY	Appl. No. 10/992,564 Patent No. 7,256,177	11-17-2004	08-14-2007
ANTIBIOTICS GE 81112 FACTORS A,B,B1, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS, AND USE THEREOF	Appl. No. 10/496,009 Patent No. 7,407,654	09-21-2004	08-05-2008
ANTIBIOTICS GE 81112 FACTORS A, B, B1, PHARMACEUTICALLY ACCEPTABLE SALTS AND COMPOSITIONS, AND USE THEREOF	Appl. No. 12/147,215 Patent No. 8,007,789	06-26-2008	08-30-2011
DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS	Appl. No. 13/566,646 Publ. No. 20130172528	08-03-2012	
DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS	Appl. No. 10/834,395 Patent No. 7,119,061	04-27-2004	10-10-2006
DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS	Appl. No. 12/476,785 Patent No. 8,143,212	06-02-2009	03-27-2012
METHODS OF ADMINISTERING DALBAVANCIN FOR TREATMENT OF BACTERIAL INFECTIONS	Appl. No. 10/714,261 Patent No. 6,900,175	11-14-2003	05-31-2005
STABLE PHARMACEUTICAL COMPOSITIONS OF DALBAVANCIN AND METHODS OF ADMINISTRATION	Appl. No. 10/828,439 Patent No. 7,115,564	04-16-2004	10-03-2006